BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) Eye-D platform insert will be presented at the 5thAnnual Partnership Opportunities in Drug Delivery conference in Boston on Oct. 5.
The Eye-D is BioLight’s platform insert for controlled release of ophthalmic medications and is designed to address the known poor compliance of eye drops administration.
The first Eye-D indication, VS-101, contains the market leading glaucoma drug, latanoprost.
Utilizing a simple in-office procedure, VS-101 is intended to release prostaglandin analog drug in a controlled manner over time, providing 100% patient compliance to drug therapy.
